IPOGrid
0001868734
IPO filing research

CinCor Pharma, Inc.

Pharmaceutical Preparations

follow-on priced 424B4

CinCor Pharma, Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: 424B4 on 2022-08-12.

Filing Timeline

SEC EDGAR
424B4 priced
Final prospectus
Final prospectus filed after pricing with final deal terms.
Follows EFFECT and confirms the priced prospectus.
2022-08-12 · 0001193125-22-219819
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows S-1 and marks the registration effective.
2022-08-10 · 9999999995-22-002327
S-1 filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS in the pre-IPO sequence.
2022-08-08 · 0001193125-22-215087
DRS filed
Draft registration statement
Draft registration filed confidentially before the public launch.
Begins the tracked draft filing sequence after 424B4.
CinCor Pharma, Inc. outlines significant challenges and risks associated with its clinical development of baxdrostat, including potential delays in regulatory approvals, difficulties in patient enrollment, and the impact of the COVID-19 pandemic. The company amended the protocol of its spark-PA trial in May 2022 to address enrollment issues related to prolonged blood pressure elevation during washout periods. Key risks include clinical trial failures, regulatory hurdles, and the financial implications of extended development timelines.
2022-07-25 · 0000950123-22-007361
424B4 priced
Final prospectus
Final prospectus filed after pricing with final deal terms.
Follows EFFECT and confirms the priced prospectus.
2022-01-07 · 0001193125-22-004577
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows CERT and marks the registration effective.
2022-01-06 · 9999999995-22-000078
CERT inactive
CERT
Pre-IPO filing captured from the SEC submission timeline.
Follows 8-A12B in the pre-IPO sequence.
2022-01-05 · 0001354457-22-000008
8-A12B effective
Exchange Act registration
Registration filed to list the securities under the Exchange Act ahead of trading.
Follows S-1/A and registers the class of securities for exchange listing.
2022-01-04 · 0001193125-22-001678
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
2022-01-03 · 0001193125-22-000240
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
2021-12-23 · 0001193125-21-365779
S-1 filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS/A in the pre-IPO sequence.
2021-12-17 · 0001193125-21-361288
DRS/A amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
2021-12-01 · 0000950123-21-015966
DRS/A amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
2021-10-14 · 0000950123-21-013104
DRS filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
2021-08-27 · 0000950123-21-011912
Comparable Deals

17 comparable deals

Healthcare & BiotechLast 18 months
Only 0 strict matches; expanded to 17 using nearest neighbors.
Showing top 8 by similarity.
+5.8%
Median day-1
53%
Above issue
-0.5%
Median week-1
-20.9%
Downside (p10)
Kardigan, Inc. KARD
2026-06-18 $400M Day 1: +37.5% Wk 1: +41.1%
same SICrecent IPO
Parabilis Medicines, Inc. PBLS
2026-06-10 $670M Day 1: +58.0% Wk 1: +30.2%
same SICrecent IPO
Seaport Therapeutics, Inc. SPTX
2026-05-01 $255M Day 1: +10.2% Wk 1: -13.9%
same SICrecent IPO
Avalyn Pharma Inc. AVLN
2026-04-30 $300M Day 1: +63.8% Wk 1: +53.9%
same SICrecent IPO
First Tracks Biotherapeutics, Inc. TRAX
2026-04-20 - Day 1: -9.3% Wk 1: -11.5%
same SICrecent IPO
Kailera Therapeutics, Inc. KLRA
2026-04-17 $625M Day 1: +62.5% Wk 1: +56.7%
same SICrecent IPO
Scribe Therapeutics, Inc. SCTX
2026-07-24 $129M Day 1: +44.3% Wk 1: +44.3%
same SIC grouprecent IPO
Generate Biomedicines, Inc. GENB
2026-02-27 $400M Day 1: -20.9% Wk 1: -22.2%
same SICrecent IPO

Recent News

No recent news stored for this issuer.